Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
US ex rel. Jeffrey Campie, et al v. Gilead Sciences, Inc.
Case Number:
15-16380
Court:
Nature of Suit:
Companies
Sectors & Industries:
-
October 03, 2017
Gilead To Take 9th Circ. Escobar Ruling To High Court
Gilead Sciences Inc. on Tuesday said it will ask the U.S. Supreme Court to review a major Ninth Circuit ruling on False Claims Act liability, arguing that it created a circuit split on the Supreme Court's landmark Escobar decision.
-
September 27, 2017
9th Circ. Won't Revisit Key FCA Ruling Against Gilead
Gilead Sciences Inc. must face a whistleblower's multibillion-dollar False Claims Act suit after the Ninth Circuit said Wednesday that it wouldn't rehear the appeal en banc, despite pleas from Gilead that the circuit misinterpreted the U.S. Supreme Court's Escobar decision.
-
August 31, 2017
PhRMA Joins Fray In Gilead's 9th Circ. FCA Battle
Trade group Pharmaceutical Research and Manufacturers of America on Thursday pressed the Ninth Circuit to revisit its revival of a major False Claims Act suit targeting suspect manufacturing by Gilead Sciences Inc., warning that the revival may force drugmakers to discontinue important products.
-
August 22, 2017
'Open Season' For FCA Plaintiffs In 9th Circ., Gilead Says
A recent Ninth Circuit ruling badly misinterpreted the U.S. Supreme Court's Escobar decision and effectively declared "open season" for False Claims Act whistleblowers to target minor regulatory violations, Gilead Sciences Inc. told the Ninth Circuit on Monday.
-
July 07, 2017
Gilead FCA Suit Satisfies Escobar, 9th Circ. Rules
The Ninth Circuit on Friday resurrected a multibillion-dollar False Claims Act suit accusing Gilead Sciences Inc. of defrauding taxpayers by concealing information about drug suppliers and contamination, saying the whistleblower suit passes muster under the U.S. Supreme Court's landmark Escobar ruling.
-
April 19, 2017
Gilead's Unapproved Drug Plant Flouted FCA, 9th Circ. Told
Two former Gilead Sciences quality control staffers asked a Ninth Circuit panel Wednesday to revive allegations Gilead illegally sought government reimbursements for drugs made at an unapproved plant in China, saying the requests violated the False Claims Act because the medications' U.S. Food and Drug Administration approvals were obtained by fraud.